Health Condition 1: N179- Acute kidney failure, unspecified
Conditions
Interventions
Intervention1: niacinamide: Vitamin b3 formulation niacinamide will be used. niacinamide will be administered 500 mg twice daily for 14 days in testing arm.
Control Intervention1: Standard Care
: IVC
Sponsors
Department of Nephrolog
Eligibility
Inclusion criteria
Inclusion criteria: Age between 18 – 70 years Diagnosis of community-acquired AKI
Exclusion criteria
Exclusion criteria: Pre-existing CKD with baseline CKD EPI eGFR High likelihood of underlying CKD as determined by treating physician based on clinical and laboratory parameters. Suspected or biopsy proven glomerulonephritis as a cause of AKI. Obstructive nephropathy as a cause of AKI. Solid-organ or bone marrow transplant recipients. High likelihood of re-hospitalization or death in the following 4 months as ascertained by treating physician. Suspected or diagnosed case of decompensated chronic liver disease or AST/ ALT more than 5 times of upper limit of normal. Suspected or diagnosed case of heart failure with functional class 3 or 4. Past or present diagnosis of malignancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure will be the renal recovery at 4-month in patients having community-acquired AKITimepoint: 4 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures will include a. all-cause mortality b. urine quinolate to tryptophan ratio after niacinamide supplementation Safety outcome measures will include: a. side effects of niacinamide b. hypersensitivity reaction after administration of intervention drug Timepoint: 1 month and 4 month | — |
Countries
India
Contacts
Public ContactDr Sahil
PGIMER
Outcome results
None listed